



ASX ANNOUNCEMENT

28 February 2022

## COMPLETION OF SHARE CONSOLIDATION

**CardieX Limited (ASX:CDX) (CardieX, the Company)** advises that following shareholder approval at the Extraordinary General Meeting on 16 February 2022, the consolidation of the issued capital of the Company on the basis of one (1) security for every ten (10) securities held is now complete.

Following the consolidation, CardieX's shares is as follows:

CDX: Ordinary Fully Paid	109,953,700
--------------------------	-------------

Where the consolidation resulted in a fraction of a Share, Performance Right or Option being held, the Company rounded that fraction up to the next whole number (as the case may be).

New holding statements have been dispatched to security holders on a post consolidation basis.

Approved by the Board of Directors and Released by Jarrod White, Director.

For more information please contact:

### Investor Relations

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

### Media Relations

Melissa Hamilton

[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

### About CardieX

CardieX is a global health technology company. Its ATCOR subsidiary is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Its CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Securities Exchange (ASX:CDX).